{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:03:56Z","timestamp":1778126636905,"version":"3.51.4"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Antimuscarinic drug toxicity is a common pediatric emergency, which produces central and peripheral symptoms. Treatment of agitation and hyperactive antimuscarinic delirium, with first-line agents like cholinesterase inhibitors or benzodiazepines, is imperative to prevent severe toxicity. Intravenous physostigmine salicylate is a cholinesterase inhibitor that is commonly used to treat central antimuscarinic delirium. Its chemical structure facilitates crossing of the blood\u2013brain barrier. Overlapping nationwide physostigmine and benzodiazepine shortages have prompted consideration of therapeutic alternatives. Rivastigmine is a long-acting cholinesterase inhibitor with a similar chemical structure to physostigmine. It represents a potential therapeutic option for antimuscarinic delirium. Rivastigmine offers potential benefits over physostigmine including a longer duration of action, slower rate of central nervous system penetration, more favorable side effect profile, and availability in multiple formulations. A paucity of literature exists describing the use of rivastigmine for central antimuscarinic delirium. We describe the effective use of oral rivastigmine in a child with central antimuscarinic delirium.<\/jats:p>","DOI":"10.1093\/omcr\/omad096","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T19:04:23Z","timestamp":1695841463000},"source":"Crossref","is-referenced-by-count":7,"title":["Treatment of pediatric antimuscarinic delirium with oral rivastigmine"],"prefix":"10.1093","volume":"2023","author":[{"given":"Brandtly","family":"Yakey","sequence":"first","affiliation":[{"name":"Detroit Medical Center Department of Emergency Medicine, , Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9471-2348","authenticated-orcid":false,"given":"Varun","family":"Vohra","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine Michigan Poison & Drug Information Center, Department of Emergency Medicine, , Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarilis","family":"Martin","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Michigan Department of Pediatrics, , Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M","family":"King","sequence":"additional","affiliation":[{"name":"Detroit Medical Center Department of Emergency Medicine, , Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"2023092719040699800_ref1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/15563650.2020.1854281","article-title":"A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome","volume":"59","author":"Wang","year":"2021","journal-title":"Clin Toxicol (Phila)"},{"key":"2023092719040699800_ref2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/15563650.2020.1818768","article-title":"Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication","volume":"59","author":"Van Kernebeek","year":"2021","journal-title":"Clin Toxicol (Phila)"},{"key":"2023092719040699800_ref3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1176\/ajp.153.2.231","article-title":"A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients","volume":"153","author":"Breitbart","year":"1996","journal-title":"Am J Psychiatry"},{"key":"2023092719040699800_ref4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0196-0644(00)70057-6","article-title":"A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning","volume":"35","author":"Burns","year":"2000","journal-title":"Ann Emerg Med"},{"key":"2023092719040699800_ref5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajem.2023.02.036","article-title":"Shortages of agents used to treat antimuscarinic delirium","volume":"67","author":"Whitledge","year":"2023","journal-title":"Am J Emerg Med"},{"key":"2023092719040699800_ref6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s13181-022-00917-z","article-title":"Benzodiazepine shortages: a recurrent challenge in need of a solution","volume":"19","author":"Whitledge","year":"2023","journal-title":"J Med Toxicol"},{"key":"2023092719040699800_ref7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/15563650.2020.1869757","article-title":"Letter in response to rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication","volume":"59","author":"Hughes","year":"2021","journal-title":"Clin Toxicol (Phila)."},{"key":"2023092719040699800_ref8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.euroneuro.2017.05.006","article-title":"Treating 'Devil\u2019s breath\u2032 intoxication: use of rivastigmine in six patients with toxic psychoses due to non pharmaceutical scopolamine","volume":"27","author":"Sandia","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"2023092719040699800_ref9","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/ajmg.a.37650","article-title":"Safety and efficacy of rivastigmine in children with down syndrome: a double blind placebo controlled trial","volume":"170","author":"Spiridigliozzi","year":"2016","journal-title":"Am J Med Genet A"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2023\/9\/omad096\/51752251\/omad096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2023\/9\/omad096\/51752251\/omad096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T19:04:30Z","timestamp":1695841470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omad096\/7281886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omad096","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,9,1]]},"article-number":"omad096"}}